TransCode announced the execution of a sponsored research agreement with Michigan State University. The agreement is designed to accelerate development of TransCode’s pipeline candidates from the laboratory into clinical development. Research conducted at MSU will also focus on evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in combination withSeviprotimut-L for potential synergies and in combination with standard-of-care therapies. TransCode acquired Seviprotimut-L through its acquisition of the parent company of Polynoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- Transcode Therapeutics signs flexible financing agreement for up to $20M
- TransCode Therapeutics Secures New Financing to Extend Runway
- TransCode Therapeutics Delays 2025 Annual Filing
- TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal
- Transcode Therapeutics enters exclusive license agreement with Unleash